GMI-1070

Names

[ Name ]:
GMI-1070

[Synonym ]:
4B115V09LB
GMI-1070
PF-06460031
(1R,2R,3S,5R)-2-[(6-Deoxy-α-L-galactopyranosyl)oxy]-3-{[(2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinyl)carbonyl]amino}-5-[(2-{[(2-{2-oxo-2-[(3,6,8-trisulfo-1-naphthyl)amino]ethoxy}ethoxy)acetyl]amino }ethyl)carbamoyl]cyclohexyl 2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexylethyl]-β-D-galactopyranoside
9776
β-D-Galactopyranoside, (1R,2R,3S,5R)-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-3-[[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)carbonyl]amino]-5-[1,6,13-trioxo-13-[(3,6,8-trisulfo-1-naphthalenyl)am ino]-8,11-dioxa-2,5-diazatridec-1-yl]cyclohexyl 3-O-[(1S)-1-carboxy-2-cyclohexylethyl]-, 2-benzoate
Rivipansel

Biological Activity

[Description]:

Rivipansel (GMI-1070) is a potent E-selectin antagonist. Rivipansel prevents interaction between leukocytes and vascular endothelium. Rivipansel has the potential for the research of sickle cell vaso-occlusive crisis[1][2].

[Related Catalog]:

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Others >> Others

[References]

[1]. Dampier CD, et al. A Randomized Clinical Trial of the Efficacy and Safety of Rivipansel for Sickle Cell Vaso-occlusive Crisis (VOC). Blood. 2022 Aug 18:blood.2022015797.

[2]. Carlton D.DampierMD, et al. Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis. Blood, 2020, 136 (1):18-19.

Chemical & Physical Properties

[ Density]:
1.7±0.1 g/cm3

[ Molecular Formula ]:
C₅₈H₇₄N₆O₃₁S₃

[ Molecular Weight ]:
1447.425

[ Exact Mass ]:
1446.356079

[ LogP ]:
-0.62

[ Index of Refraction ]:
1.693

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.